Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500.When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical devices and biotechs should perform better as the year matures, while defensive groups like pharma should perform well during the earlier part of the year.